These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 18039351

  • 21. SHP656, a polysialylated recombinant factor VIII (PSA-rFVIII): First-in-human study evaluating safety, tolerability and pharmacokinetics in patients with severe haemophilia A.
    Tiede A, Allen G, Bauer A, Chowdary P, Collins P, Goldstein B, Jiang HJ, Kӧck K, Takács I, Timofeeva M, Wolfsegger M, Srivastava S.
    Haemophilia; 2020 Jan; 26(1):47-55. PubMed ID: 31778283
    [Abstract] [Full Text] [Related]

  • 22. Increased branching and sialylation of N-linked glycans correlate with an improved pharmacokinetic profile for BAY 81-8973 compared with other full-length rFVIII products.
    Teare JM, Kates DS, Shah A, Garger S.
    Drug Des Devel Ther; 2019 Jan; 13():941-948. PubMed ID: 30962676
    [Abstract] [Full Text] [Related]

  • 23. Clinical evaluation of recombinant human factor VIII (BAY w 6240) in the treatment of hemophilia A.
    Fukui H, Yoshioka A, Shima M, Tanaka I, Koshihara K, Fukutake K, Fujimaki M.
    Int J Hematol; 1991 Oct; 54(5):419-27. PubMed ID: 1756252
    [Abstract] [Full Text] [Related]

  • 24. Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting.
    Musso R, Santagostino E, Faradji A, Iorio A, van der Meer J, Ingerslev J, Lambert T, Maas-Enriquez M, Gorina E, KOGENATE Bayer European PMS Study Group.
    Thromb Haemost; 2008 Jan; 99(1):52-8. PubMed ID: 18217134
    [Abstract] [Full Text] [Related]

  • 25. Impact of capacity-limited binding on recombinant factor VIII and von Willebrand factor pharmacokinetics in hemophilia A rats.
    Vargas Christensen I, Loftager M, Rode F, Mørck Nielsen H, Kreilgaard M, Larsen MS.
    J Thromb Haemost; 2019 Jun; 17(6):964-974. PubMed ID: 30924607
    [Abstract] [Full Text] [Related]

  • 26. Stability, efficacy, and safety of continuously infused sucrose-formulated recombinant factor VIII (rFVIII-FS) during surgery in patients with severe haemophilia.
    Martinowitz U, Luboshitz J, Bashari D, Ravid B, Gorina E, Regan L, Stass H, Lubetsky A.
    Haemophilia; 2009 May; 15(3):676-85. PubMed ID: 19298381
    [Abstract] [Full Text] [Related]

  • 27. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels.
    Shapiro AD, Ragni MV, Kulkarni R, Oldenberg J, Srivastava A, Quon DV, Pasi KJ, Hanabusa H, Pabinger I, Mahlangu J, Fogarty P, Lillicrap D, Kulke S, Potts J, Neelakantan S, Nestorov I, Li S, Dumont JA, Jiang H, Brennan A, Pierce GF.
    J Thromb Haemost; 2014 Nov; 12(11):1788-800. PubMed ID: 25196897
    [Abstract] [Full Text] [Related]

  • 28. Efficacy of standard prophylaxis versus on-demand treatment with bayer's sucrose-formulated recombinant FVIII (rFVIII-FS) in Chinese children with severe hemophilia A.
    Zhao Y, Xiao J, Yang R, Wu R, Hu Y, Beckmann H, Wu J, Hou Q, Sun J.
    Pediatr Hematol Oncol; 2017 Apr; 34(3):138-148. PubMed ID: 28727494
    [Abstract] [Full Text] [Related]

  • 29. Enhanced efficacy of recombinant FVIII in noncovalent complex with PEGylated liposome in hemophilia A mice.
    Pan J, Liu T, Kim JY, Zhu D, Patel C, Cui ZH, Zhang X, Newgren JO, Reames A, Canivel D, Jesmok G, Pierce GF, Sommer JM, Jiang H.
    Blood; 2009 Sep 24; 114(13):2802-11. PubMed ID: 19654409
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII.
    Reding MT, Ng HJ, Poulsen LH, Eyster ME, Pabinger I, Shin HJ, Walsch R, Lederman M, Wang M, Hardtke M, Michaels LA.
    J Thromb Haemost; 2017 Mar 24; 15(3):411-419. PubMed ID: 27992112
    [Abstract] [Full Text] [Related]

  • 32. Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A.
    Shah A, Solms A, Garmann D, Katterle Y, Avramova V, Simeonov S, Lissitchkov T.
    Clin Pharmacokinet; 2017 Sep 24; 56(9):1045-1055. PubMed ID: 28005225
    [Abstract] [Full Text] [Related]

  • 33. Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia.
    Mahlangu JN, Coetzee MJ, Laffan M, Windyga J, Yee TT, Schroeder J, Haaning J, Siegel JE, Lemm G.
    J Thromb Haemost; 2012 May 24; 10(5):773-80. PubMed ID: 22353395
    [Abstract] [Full Text] [Related]

  • 34. A Real-World Analysis of Commonly Prescribed FVIII Products Based on U.S. Medical Charts: Consumption and Bleeding Outcomes in Hemophilia A Patients.
    Yan S, Maro GS, Desai V, Simpson ML.
    J Manag Care Spec Pharm; 2020 Oct 24; 26(10):1258-1265. PubMed ID: 32820685
    [Abstract] [Full Text] [Related]

  • 35. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients.
    Blanchette VS, Shapiro AD, Liesner RJ, Hernández Navarro F, Warrier I, Schroth PC, Spotts G, Ewenstein BM, rAHF-PFM Clinical Study Group.
    J Thromb Haemost; 2008 Aug 24; 6(8):1319-26. PubMed ID: 18503631
    [Abstract] [Full Text] [Related]

  • 36. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A.
    Young G, Mahlangu J, Kulkarni R, Nolan B, Liesner R, Pasi J, Barnes C, Neelakantan S, Gambino G, Cristiano LM, Pierce GF, Allen G.
    J Thromb Haemost; 2015 Jun 24; 13(6):967-77. PubMed ID: 25912075
    [Abstract] [Full Text] [Related]

  • 37. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A.
    Tiede A, Brand B, Fischer R, Kavakli K, Lentz SR, Matsushita T, Rea C, Knobe K, Viuff D.
    J Thromb Haemost; 2013 Apr 24; 11(4):670-8. PubMed ID: 23398640
    [Abstract] [Full Text] [Related]

  • 38. Continuous infusion of recombinant factor VIII formulated with sucrose in surgery: non-interventional, observational study in patients with severe haemophilia A.
    Meijer K, Rauchensteiner S, Santagostino E, Platokouki H, Schutgens RE, Brunn M, Tueckmantel C, Valeri F, Schinco PC.
    Haemophilia; 2015 Jan 24; 21(1):e19-25. PubMed ID: 25458982
    [Abstract] [Full Text] [Related]

  • 39. Report on 4 cases with decreased recovery due to neutralizing antibodies specific for PEGylated recombinant factor VIII.
    Hillarp A, Holme PA, Wåland EP, Le MS, Henriksson CE, Tjønnfjord GE, Måseide RJ.
    J Thromb Haemost; 2023 Oct 24; 21(10):2771-2775. PubMed ID: 37543216
    [Abstract] [Full Text] [Related]

  • 40. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme.
    Oldenburg J, Windyga J, Hampton K, Lalezari S, Tseneklidou-Stoeter D, Beckmann H, Maas Enriquez M.
    Haemophilia; 2016 May 24; 22(3):349-53. PubMed ID: 26931631
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.